PDF(Pubmed)
Abstract：
UNASSIGNED: Systemic therapies for refractory meningiomas are limited with no FDA-approved therapeutics. Vascular endothelial growth factor (VEGF) is a signaling protein associated with neovascularization, peritumoral edema, and meningioma tumorigenesis.
UNASSIGNED: This phase II study investigates the efficacy of bevacizumab (BEV), a VEGF binding monoclonal antibody, in patients with progressive Grade I (G1M), Grade II (G2M), Grade III (G3M) meningioma, and other non-parenchymal tumors including vestibular schwannoma (n = 4) and hemangiopericytoma (n = 4) with the primary endpoint of progression-free survival rate at 6-months (PFS-6). Non-meningiomas were included with the respective meningioma grade in the analysis. Secondary endpoints include median overall survival (mOS) and response rate.
UNASSIGNED: Fifty Patients (26 women; median age 54 years; range 23-81), 42 with progressive meningioma were treated: 10 G1M, 20 G2M, and 12 G3M. Prior treatments include surgical resection (41 patients), radiosurgery (24 patients), external beam radiotherapy (28 patients), and chemotherapy (14 patients). Median infusions administered were 16 (range, 2-68). Response was graded using the Macdonald\'s criteria. PFS-6, median PFS, and mOS were 87%, 22 months, 35 months for G1M; 77%, 23 months, 41 months for G2M; and 46%, 8 months, 12 months for G3M. Best radiographic responses include stable disease (G1M: 100%; G2M: 85%; G3M: 82%); partial response (G1M: 0%; G2M: 5%; G3M: 0%) and progressive disease (G1M: 0%; G2M: 10%; G3M:18%). The most common toxicities were hypertension (n = 19, 42.2%), proteinuria (n = 16, 35.6%), and fatigue (n = 14, 31.1%).
UNASSIGNED: This study showed BEV is well tolerated and appears to be a promising systemic treatment option for patients with recurrent and refractory meningiomas.
UNASSIGNED: This phase II study investigates the efficacy of bevacizumab (BEV), a VEGF binding monoclonal antibody, in patients with progressive Grade I (G1M), Grade II (G2M), Grade III (G3M) meningioma, and other non-parenchymal tumors including vestibular schwannoma (n = 4) and hemangiopericytoma (n = 4) with the primary endpoint of progression-free survival rate at 6-months (PFS-6). Non-meningiomas were included with the respective meningioma grade in the analysis. Secondary endpoints include median overall survival (mOS) and response rate.
UNASSIGNED: Fifty Patients (26 women; median age 54 years; range 23-81), 42 with progressive meningioma were treated: 10 G1M, 20 G2M, and 12 G3M. Prior treatments include surgical resection (41 patients), radiosurgery (24 patients), external beam radiotherapy (28 patients), and chemotherapy (14 patients). Median infusions administered were 16 (range, 2-68). Response was graded using the Macdonald\'s criteria. PFS-6, median PFS, and mOS were 87%, 22 months, 35 months for G1M; 77%, 23 months, 41 months for G2M; and 46%, 8 months, 12 months for G3M. Best radiographic responses include stable disease (G1M: 100%; G2M: 85%; G3M: 82%); partial response (G1M: 0%; G2M: 5%; G3M: 0%) and progressive disease (G1M: 0%; G2M: 10%; G3M:18%). The most common toxicities were hypertension (n = 19, 42.2%), proteinuria (n = 16, 35.6%), and fatigue (n = 14, 31.1%).
UNASSIGNED: This study showed BEV is well tolerated and appears to be a promising systemic treatment option for patients with recurrent and refractory meningiomas.
摘要：
未经批准：难治性脑膜瘤的全身疗法有限，没有FDA批准的疗法。血管内皮生长因子（VEGF）是一种与新生血管形成相关的信号蛋白，瘤周水肿，和脑膜瘤的肿瘤发生。
未经评估：这项II期研究调查了贝伐单抗（BEV）的疗效，VEGF结合单克隆抗体，在进行性I级（G1M）患者中，二级(G2M),III级(G3M)脑膜瘤,和其他非实质肿瘤，包括前庭神经鞘瘤（n=4）和血管外皮细胞瘤（n=4），主要终点为6个月无进展生存率（PFS-6）。非脑膜瘤包括在分析中的相应脑膜瘤等级。次要终点包括中位总生存期(mOS)和缓解率。
未经评估：50名患者（26名女性；平均年龄54岁；范围23-81），治疗42例进行性脑膜瘤：10G1M，20G2M,12G3M先前的治疗包括手术切除（41例），放射外科（24名患者），外束放疗（28例），和化疗（14例）。中位输注次数为16次(范围，2-68).使用麦克唐纳的标准对反应进行分级。PFS-6，中位数PFS，MOS为87%,22个月,G1M为35个月；77%，23个月,G2M为41个月；46%，8个月,12个月为G3M。最佳放射学应答包括疾病稳定(G1M:100%;G2M:85%;G3M:82%);部分应答(G1M:0%;G2M:5%;G3M:0%)和疾病进展(G1M:0%;G2M:10%;G3M:18%)。最常见的毒性是高血压（n=19，42.2%），蛋白尿（n=16，35.6%），和疲劳(n=14，31.1%)。
UNASSIGNED：这项研究表明，BEV具有良好的耐受性，似乎是复发性和难治性脑膜瘤患者的一种有希望的全身治疗选择。
未经评估：这项II期研究调查了贝伐单抗（BEV）的疗效，VEGF结合单克隆抗体，在进行性I级（G1M）患者中，二级(G2M),III级(G3M)脑膜瘤,和其他非实质肿瘤，包括前庭神经鞘瘤（n=4）和血管外皮细胞瘤（n=4），主要终点为6个月无进展生存率（PFS-6）。非脑膜瘤包括在分析中的相应脑膜瘤等级。次要终点包括中位总生存期(mOS)和缓解率。
未经评估：50名患者（26名女性；平均年龄54岁；范围23-81），治疗42例进行性脑膜瘤：10G1M，20G2M,12G3M先前的治疗包括手术切除（41例），放射外科（24名患者），外束放疗（28例），和化疗（14例）。中位输注次数为16次(范围，2-68).使用麦克唐纳的标准对反应进行分级。PFS-6，中位数PFS，MOS为87%,22个月,G1M为35个月；77%，23个月,G2M为41个月；46%，8个月,12个月为G3M。最佳放射学应答包括疾病稳定(G1M:100%;G2M:85%;G3M:82%);部分应答(G1M:0%;G2M:5%;G3M:0%)和疾病进展(G1M:0%;G2M:10%;G3M:18%)。最常见的毒性是高血压（n=19，42.2%），蛋白尿（n=16，35.6%），和疲劳(n=14，31.1%)。
UNASSIGNED：这项研究表明，BEV具有良好的耐受性，似乎是复发性和难治性脑膜瘤患者的一种有希望的全身治疗选择。
